SEC Form 4 · accession 0001106578-26-000068
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairperson & CEO · Director
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 4:34 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 2, 2026 | M | 9,500 | $146.03 | A | 50,013 | D | |
| Common StockF2 | Jun 2, 2026 | S | 1,160 | $535.6862 | D | 48,853 | D | |
| Common StockF3 | Jun 2, 2026 | S | 2,056 | $536.615 | D | 46,797 | D | |
| Common StockF4 | Jun 2, 2026 | S | 1,464 | $537.6202 | D | 45,333 | D | |
| Common StockF5 | Jun 2, 2026 | S | 1,149 | $538.8087 | D | 44,184 | D | |
| Common StockF6 | Jun 2, 2026 | S | 2,310 | $539.8255 | D | 41,874 | D | |
| Common StockF7 | Jun 2, 2026 | S | 641 | $540.4848 | D | 41,233 | D | |
| Common StockF8 | Jun 2, 2026 | S | 440 | $541.6764 | D | 40,793 | D | |
| Common StockF9 | Jun 2, 2026 | S | 280 | $543.26 | D | 40,513 | D | |
| Common Stock | holding | — | — | — | 166 | I | by Spouse | |
| Common StockF10 | holding | — | — | — | 324,443 | I | by Trust | |
| Common StockF11 | holding | — | — | — | 249,108 | I | by Trust | |
| Common StockF12 | holding | — | — | — | 45,596 | I | by Trust | |
| Common StockF13 | holding | — | — | — | 8,902 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | $146.03 | Jun 2, 2026 | M | 9,500 | D | Mar 15, 2020 | Mar 15, 2027 | Common Stock | 9,500 | 116,910 | D |
Explanation of responses
- F1This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.
- F10Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F11Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F13Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F2This transaction was executed in multiple trades at prices ranging from $535.16 to $536.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $536.16 to $537.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $537.17 to $538.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $538.24 to $539.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $539.25 to $540.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $540.25 to $540.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8This transaction was executed in multiple trades at prices ranging from $541.41 to $542.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9This transaction was executed in multiple trades at prices ranging from $543.12 to $543.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.